NES ZIONA, Israel -
- Intradermal Delivery of Vaccines can Provide Significant Dose Sparing Urgently Required in the Swine H1N1 Pandemic
Following the World Health Organization (WHO) declaration of a swine flu pandemic,[1] NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines.
“As declared by WHO on June 11th, 2009″, said Dr Yotam Levin, the Company’s CEO, “the novel A H1N1 influenza has become a phase 6 global pandemic. There is an imminent need of developing countries, as well as that of many developed countries, for an adequate supply of pandemic flu vaccines. Since global capacity is limited and production yield is reported to be low, novel approaches for vaccine enhancement are of great need.” Dr Ofer Sharon, the Company’s Medical Director added, “NanoPass has proven in a randomized clinical trial, recently published in Vaccine,[2] that it can reduce the dose of a seasonal flu vaccine by 80% while preserving its efficacy. This effect is thought to be achieved by targeting the potent specialized immune cells that reside in the skin. This means that health authorities can use the same amount of vaccine they have sourced, to vaccinate at least double, if not triple, the number of subjects, with the same vaccine purchase.” NanoPass is designing clinical studies to demonstrate this significant effect for swine H1N1.
The major global public threat posed by the new H1N1 flu strain demands close coordination among vaccine manufacturers, governments, technology developers and global health authorities to manage the supply of vaccines and to ensure there are enough doses for everyone.
About NanoPass’s MicronJet Device
MicronJet is a microneedle-based device for intradermal delivery of vaccines. The device allows for consistent, reliable, and simple delivery of the vaccine directly into the skin. It has been shown in multiple clinical trials,[3,4] that injecting a seasonal influenza vaccine directly into the skin harnesses this very potent immune organ, and allows for both the reduction of the dose required for the same immune response (”dose sparing”), as well as the ability to actually potentiate this response, with the use of equivalent doses (”increased immunogenicity”).[5]
This approach is being tested for a variety of major diseases that do not yet have an effective vaccine, such as malaria, HIV and tuberculosis.
NanoPass - Transforming device innovation into global health solutions
NanoPass, founded by Dr Shuki Yeshurun, is an Israeli-based private company developing an innovative delivery device for the enhancement of vaccines and other large molecules. The Company has proven efficacy and safety in multiple applications including seasonal flu, insulin delivery and lidocaine for local anesthesia. MicronJet is approved for marketing in the EU (please see www.nanopass.com for more information), and is about to be registered in additional markets. The MicronJet is approved for use by health care professionals for intradermal delivery of drugs and medicinal products that are approved for intradermal delivery.
References [1]www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.) [2] Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O and Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2009 Jan 14;27(3):454-9. [3] Belshe RB, Newman, FK et al. Serum Antibody Responses after Intradermal Vaccination against Influenza. N Engl J Med 2004;351:2286-94. [4] Kenney RT, Frech SA et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3. [5] Holland D, Booy R et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. JID 2008; 198:650-58.
Contact: Yotam Levin: +972-8-9313099 or +972-523-392727 or yotam@nanopass.com
Source: NanoPass Technologies LTD.
Contact: Yotam Levin: +972-8-9313099 or +972-523-392727 or yotam at nanopass.com
Related Press Releases
Milliman Estimates Impact of Swine Flu on Employer Revenue and ProfitsSeptember 9th, 2009 LONDON -
Modelling carried out by Milliman actuaries estimates that a severe swine flu pandemic has the potential to reduce a typical UK employer's revenue by 4%-5% and its profit rate by five to six percentage points during the quarter of the pandemic. Actuaries at the international consulting firm Milliman estimate that even a moderate pandemic influenza scenario could reduce a typical employer's revenue by 2% and profit rate by two to three percentage points.
Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A StrainsAugust 26th, 2009 SARASOTA, Florida -
Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Lakewood-Amedex's nRNA product works by selectively silencing targeted genes in the viral genome.
Elsevier Global Medical News Launches H1N1 ChannelAugust 17th, 2009 MORRISTOWN, New Jersey - An H1N1 influenza channel has been added to the Elsevier Global Medical News (EGMN) wire service division of the International Medical News Group. The H1N1 channel was created to meet physicians' continuing needs to keep up-to-date with the news about the spread of the 2009 H1N1 influenza virus, as well as the new diagnostics, vaccines, clinical trials, and treatments for H1N1 infections.
Viroblock SA Reports a 99% Boost of Efficacy of Facemasks Against H5N1May 4th, 2009 PLAN-LES-OUATES, Switzerland - Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1.
Maplecroft Flu Pandemic Maps Reveal Countries Most at RiskApril 30th, 2009 LONDON - With swine flu topping the agenda of business around the world, global risks specialist, Maplecroft has released three new maps and indices revealing the countries most at risk from an influenza pandemic. The Influenza Pandemic Risk Index (IPRI) consists of three categories: Risk of Emergence, Risk of Spread and Capacity to Contain.
Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company OctapharmaApril 30th, 2009 LACHEN, Switzerland - Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives
The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma. But it has reiterated the safety of its plasma derivatives and is working closely with health authorities and plasma suppliers to maintain the safety profile and continuous supply of its lifesaving products.
Are we Ignoring H2N3 at our Peril?April 30th, 2009 LONDON - Everyone is Blaming H1N1, but Could a Different Strain of Influenza be the Cause of Mexican Deaths? Clinica - The Medical Technology Industry's Leading News Source - Wonders What Implications This Would Have for Mexico and the Rest of the World
Clinica is investigating the details and significance of Mexican health ministry statements that the H2N3 influenza virus was responsible for "the majority of cases tested" in an influenza outbreak in early April, three weeks before H1N1 came on the scene. The existence of an additional strain of the disease raises fundamental questions concerning the management of the swine flu epidemic internationally.
Arrayit to Mass Produce Rapid H1N1 Swine Flu Test ChipApril 29th, 2009 SUNNYVALE, California - Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The Arrayit test will allow researchers and clinicians to detect the presence of the virus in infected patients and livestock and to distinguish the threatening mutated strain from less harmful variants in humans and swine.
Face Mask That Kills Swine Flu Readied for Fight Against PandemicApril 26th, 2009 HONG KONG - Filligent, the Hong Kong-based biotech company, is mobilizing stocks of its anti-infective BioMask to help combat the global spread of the deadly new Mexican strain of Influenza A. The BioMask is the first medical face mask to kill the Influenza A virus within seconds of contact while retaining the breathability required by front-line workers and children, who are often the first to fall in a contagious episode.
Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal SprayMarch 30th, 2009 GENEVA, Switzerland - Viroblock SA has announced today that the first generation of
VCCD Tech antiviral nasal spray formulation is active against human
influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology
(VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by
altering and destabilizing cholesterol-rich viral envelopes.
Related News
Swiss drugmaker Novartis says produces first batch of swine flu vaccine grown in cellsJune 12th, 2009 Novartis produces first batch of swine flu vaccineBASEL, Switzerland — Swiss pharmaceuticals company Novartis AG said Friday it has produced a first batch of experimental swine flu vaccine, a day after the World Health Organization declared the disease a pandemic. The vaccine hasn't yet been tested and cannot be used in humans yet.
Obama: US will share 10 percent of swine flu vaccines with other nationsSeptember 17th, 2009 US to share 10 percent swine flu vaccine globallyWASHINGTON — President Barack Obama says the United States will share 10 percent of its swine flu vaccine supply with other nations to help fight the deadly virus' global spread. The White House on Thursday announced that flu vaccines to counter the virus known among scientists as H1N1 would be available through the World Health Organization.
Swine flu 'most serious concern' for world: UN chiefApril 27th, 2009 NEW YORK - UN Secretary-General Ban Ki-moon said here Monday the outbreak of swine flu 'has become one of the most serious concerns of the international community', and called for 'global solidarity' to fight the epidemic. Ban, in a statement he read out to the press, said: 'We are concerned that this (swine flu) virus would cause a new influenza pandemic.'
'If we are indeed facing a pandemic, we need to demonstrate global solidarity,' Ban said.
WHO: Pandemic flu vaccine output will be 'substantially less' than previous maximum predictionSeptember 18th, 2009 WHO: Pandemic flu vaccine production to fall shortGENEVA — Global production of swine flu vaccines will be "substantially less" than the previous maximum forecast of 94 million doses a week, the World Health Organization said Friday. The number of doses produced in a year will therefore fall short of the 4.9 billion doses the global health body previously hoped could be available for the pandemic, WHO spokesman Gregory Hartl told reporters in Geneva.
Face masks could protect against swine flu pandemicApril 28th, 2009 SYDNEY - Donning a face-mask is an easy way to protect oneself from severe respiratory illnesses like swine flu when vaccines are unavailable or in short supply, according to a study. In the first ever clinical trial of the efficacy of masks, researchers found adult mask wearers at home were four times more likely than non-wearers to be protected against a range of respiratory viruses, including influenza, SARS and even the common cold.
Drugmakers rush to make a swine flu vaccine, but politics may complicate who actually gets itJune 12th, 2009 Drugmakers rush to produce a swine flu vaccineLONDON — With swine flu now an official pandemic, the race is on among drugmakers to produce a vaccine. GlaxoSmithKline said Thursday after the World Health Organization declared a global flu epidemic that it would be ready within weeks to begin large-scale vaccine production.
Economists tot up cost of possible pandemicApril 27th, 2009 SYDNEY - Even a mild influenza pandemic could cost 1.4 million lives and $330 billion in lost production worldwide, Australian economists have estimated. At the other end of the scale, a massive pandemic would kill 142 million people and lop $4.4 trillion off production.
UN health agency's flu chief: safety of swine flu vaccine 'cannot be compromised'July 24th, 2009 WHO flu chief: No compromise on vaccine safetyGENEVA — The World Health Organization's flu chief says there must be no doubt over the safety of swine flu vaccines before they are given to the public. Keiji Fukuda says health officials and drug makers are looking into ways of speeding up the production of the vaccine before the northern hemisphere enters its flu season in the fall.
Novartis says its swine flu vaccine may work with just 1 dose, potentially boosting suppliesSeptember 3rd, 2009 Novartis swine flu vaccine may work on fewer dosesBARCELONA, Spain — Swiss drugmaker Novartis said Thursday one of its swine flu vaccines may work with just one dose, rather than two as previously expected, yet another finding that could potentially boost global supplies. On Thursday, China approved a swine flu vaccine which its producer, Sinovac, says also works with just one dose.
Most health workers may stay away during pandemicMay 14th, 2009 LONDON - As many as 85 percent of healthcare workers may stay off work if an influenza pandemic struck a country, according to a survey. The results suggest that levels of absenteeism may be significantly higher than current official estimates and that 'willingness', rather than 'ability', plays the largest role in healthcare workers' decisions on whether to go to work or not.
